Advanced Precision Therapies For Cancer




SNAP Technology Platform
Novel precision medicine technology platform designed to transform the treatment of cancer by addressing the challenges of first-generation cell therapies targeting solid tumors
Best-in-Class Therapeutic Cancer Vaccines
Lead Program: SNAPduo 101 peptide cancer vaccine for virus-associated cancers will begin clinical testing in 2026
Proprietary Specific Neo-Antigen Peptides (SNAP) Technology Platform
Developed by Dr. Sunil Sharma and his team at the Translational Genomics Research Institute (TGen), part of the City of Hope Medical Network.
Dr. Sharma is one of the nation’s leading experts in creating anti-cancer drugs and has recently been named director of HonorHealth Research Institute’s new Center for Translational Science.
Our SNAP Technology Platform is a Major Step Forward for Targeted Therapy
- High-impact technology translating neoantigen identification to the clinic
- Direct biological confirmation of immunogenicity for individual neoantigens
- Only platform that identifies functionally validated both HLA Class I and II antigens for cancer vaccines
- Differentiated patient-specific treatment for both immunological “hot” and “cold” tumors

Team
Our Team has decades of proven experience and leadership in biopharma; supported by a network of expert advisors.

Kenneth Carter, PhD
Co-Founder & Executive Chairman

Sunil Sharma, MD, FACP, MBA
Co-Founder & CMO

Corey Casper, MD, MPH
CSO

Michael King, MBA
Co-Founder & CFO

Juan Montesinos, MD MS
Co-Founder & COO

Daniel-Paul Bednarík, PhD
CTO

Raffaela Soldi, PhD
VP of Research

Alexis Weston
Director of Strategy